RESOURCES & PERSPECTIVES

  1. Solutions For Sponsors Utilizing Drafted Guidance For PROs In Oncology 11/20/2024

    Explore the challenges pharmaceutical companies face in implementing PROs in cancer clinical trials as outlined in the FDA’s draft guidance, as well as strategies to overcome these obstacles.

  2. Antibody-Drug Conjugates In Oncology: Revolutionizing Cancer Treatment 11/20/2024

    ADCs are reshaping cancer treatment by combining targeted delivery with potent cell-killing agents. Learn how these therapies offer new hope for patients and exciting opportunities for drug developers.

  3. The Tale Of Two Clinical Supply Chains: The Risks Of Fragmented Systems 10/21/2024

    Here we examine two contrasting approaches to showcase how a centralized inventory management system is an effective tool for supporting a robust supply chain.

  4. Study, Not Software: Aligning RTSM To The Protocol 10/21/2024

    How can RTSM platforms improve your clinical trial and how do they integrate with your crucial trial systems?

  5. Simplifying The Vineland-3: Assisting Raters, Reducing Burden, And Improving Data Quality 10/21/2024

    Electronic versions of both Vineland-II and Vineland-3 have been developed with features to improve data accuracy and consistency such as built-in prompts, item-specific scoring guidance, and automated calculations.

  6. Placebo Response In Clinical Trials: Challenges And Mitigation 10/21/2024

    Explore clinical trial strategies involving tailored, culturally sensitive mitigation that will allow you to navigate the complexity of placebo response.

  7. Optimizing Prader-Willi Syndrome Clinical Trials 10/21/2024

    Learn how Signant is helping to mitigate placebo responses and ensuring high-quality data to improve Prader-Willi syndrome (PWS) clinical trial success.

  8. Why Capturing Pro Data Matters In Early-Phase Oncology Trials 9/26/2024

    If you are in the early stages of an oncology trial, there is a lot to consider when it comes to your data management and how the process can be simplified by improving how your study captures data.

  9. Opportunities For Enhancing Signal Detection In Schizophrenia Trials 9/18/2024

    Signal detection in schizophrenia trials is hindered by increased placebo response, complex rating scales, inconsistent rater performance, and data quality issues.

  10. Key Considerations Around Underrepresented Populations In Clinical Trials 9/18/2024

    Learn why increasing diversity and accessibility in clinical trials is crucial for equitable healthcare outcomes and how to address the barriers faced by underrepresented groups.